Journal
MULTIPLE SCLEROSIS AND RELATED DISORDERS
Volume 22, Issue -, Pages 38-40Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.msard.2018.02.031
Keywords
Multiple sclerosis; Autoimmune diseases
Categories
Funding
- Biogen Idec
- Merck
- Genzyme
- Novartis
- Biogen
- Teva
- Biogen Novartis
Ask authors/readers for more resources
Several reports indicate increased disease activity in patients with multiple sclerosis (MS) undergoing assisted reproductive techniques (ART), in the form of gonadtopin releasing hormone (GnRH) agonists. Other forms of ART treatments, like gonadotropin-treatment, have therefore been considered a safer option for MS-patients. We present a patient who despite being completely clinically and radiologically stable for eight years during disease modifying therapy experienced a nearly fulminant disease course almost immediately after starting gonadotropin- treatment, indicating that this form of follicle stimulating treatment could also be a major risk factor for MS disease activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available